Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$839M |
| 2 |
Amazon
AMZN
|
+$810M |
| 3 |
Tesla
TSLA
|
+$644M |
| 4 |
TSMC
TSM
|
+$546M |
| 5 |
Johnson & Johnson
JNJ
|
+$389M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$891M |
| 2 |
Home Depot
HD
|
+$441M |
| 3 |
JPMorgan Chase
JPM
|
+$335M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$317M |
| 5 |
ASML
ASML
|
+$315M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.81% |
| 2 | Technology | 15.51% |
| 3 | Consumer Discretionary | 11.84% |
| 4 | Consumer Staples | 10.09% |
| 5 | Financials | 9.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3151
XBiotech
XBIT
$68.9M
| $356K | ﹤0.01% |
101,468
-54,000
| -35% | -$184K |
|
|
VTLE
3152
DELISTED
Vital Energy
VTLE
| $355K | ﹤0.01% |
6,900
-113,330
| -94% | -$7M |
|
3153
Midland States Bancorp
MSBI
$709M
| $354K | ﹤0.01% |
13,300
+500
| +4% | +$13.3K |
|
3154
First Trust Nasdaq Oil & Gas ETF
FTXN
$158M
| $352K | ﹤0.01% |
+12,600
| New | +$363K |
|
3155
Standard BioTools
LAB
$306M
| $351K | ﹤0.01% |
300,100
-44,000
| -13% | -$54.2K |
|
3156
LCI Industries
LCII
$2.58B
| $351K | ﹤0.01% |
3,800
-55,400
| -94% | -$5.44M |
|
3157
State Street SPDR Portfolio Long Term Treasury ETF
SPTL
$10.6B
| $351K | ﹤0.01% |
12,100
-107,300
| -90% | -$3.14M |
|
|
AFIB
3158
DELISTED
Acutus Medical Inc
AFIB
| $350K | ﹤0.01% |
304,500
-98,200
| -24% | -$81.1K |
|
|
AMYT
3159
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
| $350K | ﹤0.01% |
48,000
+300
| +0.6% | +$2.12K |
|
3160
Cheer Holding
CHR
$3.62M
| $349K | ﹤0.01% |
159
+138
| +657% | +$309K |
|
|
TRHC
3161
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
| $349K | ﹤0.01% |
70,600
-115,800
| -62% | -$477K |
|
3162
Core Laboratories
CLB
$522M
| $345K | ﹤0.01% |
+17,000
| New | +$330K |
|
3163
Federal Signal
FSS
$7.91B
| $344K | ﹤0.01% |
+7,402
| New | +$340K |
|
3164
iShares Global Financials ETF
IXG
$686M
| $344K | ﹤0.01% |
4,900
-400
| -8% | -$27.3K |
|
3165
Mid Penn Bancorp
MPB
$965M
| $344K | ﹤0.01% |
+11,469
| New | +$369K |
|
3166
New Fortress Energy
NFE
$96.1M
| $344K | ﹤0.01% |
8,100
-216,200
| -96% | -$10.4M |
|
3167
Invesco S&P 500 Pure Value ETF
RPV
$1.67B
| $343K | ﹤0.01% |
4,400
-7,500
| -63% | -$585K |
|
3168
Dine Brands
DIN
$451M
| $342K | ﹤0.01% |
+5,300
| New | +$369K |
|
|
ZYXI
3169
DELISTED
Zynex
ZYXI
| $342K | ﹤0.01% |
24,562
+7,200
| +41% | +$87K |
|
3170
ProShares Short High Yield
SJB
$47.7M
| $340K | ﹤0.01% |
17,900
-69,000
| -79% | -$1.32M |
|
3171
Outfront Media
OUT
$5.6B
| $338K | ﹤0.01% |
+20,726
| New | +$350K |
|
3172
State Street SPDR S&P 400 Mid Cap Value ETF
MDYV
$2.82B
| $337K | ﹤0.01% |
+5,200
| New | +$334K |
|
3173
GDS Holdings
GDS
$6.39B
| $336K | ﹤0.01% |
+16,300
| New | +$249K |
|
|
XYF
3174
X Financial
XYF
$202M
| $336K | ﹤0.01% |
111,175
-9,200
| -8% | -$20.4K |
|
|
YI
3175
111 Inc
YI
$34.2M
| $336K | ﹤0.01% |
11,135
| – | – |
|
Similar funds
Renaissance Technologies's Q4 2022 Portfolio in Review
As of Q4 2022, Renaissance Technologies held 4,601 positions worth $73.1B, up 3.4% from $70.7B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Renaissance Technologies's Q4 2022 filing shows 626 new, 1,390 increased, 2,018 reduced and 524 closed positions. Its largest new stake was Johnson & Johnson: 2,254,125 shares worth $398M. The largest sale was Microsoft, an estimated $891M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Renaissance Technologies's largest Q4 2022 buy was Johnson & Johnson: 2,254,125 shares worth $398M.
- Renaissance Technologies added most to Apple in Q4 2022, an estimated $839M increase.
- Renaissance Technologies's biggest Q4 2022 reduction was Novo Nordisk, cutting an estimated $317M.
- Renaissance Technologies fully exited Microsoft in Q4 2022, selling an estimated $891M.
- Renaissance Technologies's ten largest holdings make up 11% of its $73.1B portfolio in Q4 2022.
- Renaissance Technologies opened 626 new positions and closed 524 in Q4 2022.
- Renaissance Technologies's portfolio value rose 3.4% quarter-over-quarter to $73.1B.
Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.